anti-CD20/anti-CD3/anti-CD8 trispecific antibody AZD5492

A trispecific immunoglobulin G (IgG)-like T-cell engaging (TCE) antibody targeting the tumor-associated antigen (TAA) CD20 and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD20/anti-CD3/anti-CD8 trispecific antibody AZD5492 targets and binds to CD20 on CD20-expressing tumor B-cell, and the CD3 and CD8 antigens on CD8-positive T lymphocytes. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor cells. CD20, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies.